InspireMD is currently navigating a high-stakes transition as it attempts to leverage 122.2% year-over-year revenue growth to support its U.S. clinical trial ambitions. While international market adoption of the CGuard system appears to be gaining traction, th...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 17, 2026 | -$0.17+15.0% vs -$0.20 | $2M+28.1% vs $1M |
Q2 2026 May 4, 2026 | -$0.16+15.8% vs -$0.19 | $3M+25.8% vs $3M |
Q2 2026 Mar 18, 2026 | -$0.14+36.4% vs -$0.22 | $3M+19.9% vs $3M |
Q4 2025 Nov 4, 2025 | -$0.17+0.0% vs -$0.17 | $3M-3.9% vs $3M |
- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 -
MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 23,764 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of September 2, 2026, as an inducement material to the non-executive employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C.
InspireMD (NSPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Benchmark NSPR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for InspireMD, Inc. (NSPR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.62 | $29.16M | -0.82 | 28.11% | -543.33% | -106.88% | — | |
| $28.10 | $232.67M | 32.67 | 16.97% | 15.32% | 23.38% | — | |
| $10.03 | $1.54B | -10.45 | 24.95% | -13.5% | -818.99% | — | |
| $15.11 | $624.53M | -17.17 | 9.46% | -11.48% | -21.01% | — | |
| $140.06 | $9.01B | -68.32 | -89.41% | 29.4% | 12.03% | — | |
| $86.38 | $110.9B | 23.16 | 8.43% | 13.93% | 10.51% | — |
InspireMD, Inc. (NSPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
InspireMD, Inc. (NSPR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 17, 2026·SEC
Jul 29, 2026·SEC
Jul 23, 2026·SEC
Get notified when NSPR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
InspireMD, Inc. (NSPR) stock FAQ — growth, dividends, profitability & financials explained
InspireMD, Inc. (NSPR) reported $10.8M in revenue for fiscal year 2025. This represents a 218% increase from $3.4M in 2009.
InspireMD, Inc. (NSPR) grew revenue by 28.1% over the past year. This is strong growth.
InspireMD, Inc. (NSPR) reported a net loss of $38.5M for fiscal year 2025.
InspireMD, Inc. (NSPR) has a return on equity (ROE) of -106.9%. Negative ROE indicates the company is unprofitable.
InspireMD, Inc. (NSPR) had negative free cash flow of $42.5M in fiscal year 2025, likely due to heavy capital investments.
